Article
Chemistry, Multidisciplinary
Hyeonwoo Je, Gi-Hoon Nam, Gi Beom Kim, Wonjun Kim, Soo Rin Kim, In-San Kim, Eun Jung Lee
Summary: TRAIL shows promising anti-tumor activity, but faces challenges such as resistance and delivery issues. A nanocage has been developed to efficiently deliver TRAIL and a re-sensitizing drug (DOX) to overcome TRAIL-resistant tumors, demonstrating potential as an effective antitumor agent.
JOURNAL OF CONTROLLED RELEASE
(2021)
Review
Chemistry, Inorganic & Nuclear
Antonello Merlino
Summary: This article highlights the binding between anticancer metallodrugs and human serum albumin (HSA), as well as the effect on HSA structure. The study discusses the possibility of using metallodrug/HSA adducts as anticancer agents. It is found that metal compounds can bind with HSA through coordinative bonds and non-covalent interactions, primarily at specific binding sites in the HSA structure, such as Cys34, His105, His146, etc. This research can contribute to the design of new metallodrugs with improved pharmacokinetics and tumor targeting.
COORDINATION CHEMISTRY REVIEWS
(2023)
Article
Biochemistry & Molecular Biology
Xiaotong Zhao, Radostina Georgieva, Pichayut Rerkshanandana, Moritz Hackmann, Lara-Elena Heil Olaizola, Maxine Mueller-de Ahna, Hans Baeumler
Summary: The co-localization of platelets and tumor cells in hematogenous metastases has been recognized for a long time. Interactions between platelets and circulating tumor cells contribute to tumor cell survival and migration. Researchers have developed modified human serum albumin submicron particles (HSA-MPs) targeted towards tumor cells by taking advantage of the interactions between platelets and tumor cells. In vitro experiments have shown the adhesion of HSA-MPs to platelets and the uptake of these particles by tumor cells mediated by activated platelets. These platelet-based and platelet-mimicking HSA-MPs could hold promise for tracking metastatic cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Neurosciences
Xiaokun Zhou, Liang Lv, Yuan Tan, Zhongyi Zhang, Shuyang Wei, Shaowen Xiao
Summary: The study demonstrates that Tanshinone IIA enhances TRAIL-induced apoptosis in glioblastoma cells by modulating the expression of STAT3, DR4, and DR5. In vivo experiments show that cotreatment with T-IIA and TRAIL effectively inhibits tumor growth and induces apoptosis in nude mice.
Article
Biochemistry & Molecular Biology
Chrysi Koliaki, Nicholas Katsilambros
Summary: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has a protective role in the development of diabetes mellitus, but further research is needed to understand the underlying mechanisms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
Haixu Yu, Wei Rong, Jie Yang, Jie Lu, Ke Ma, Zhuohui Liu, Hui Yuan, Lei Xu, Yulin Li, Zhi-Cheng Jing, Jie Du
Summary: This study found that reduced plasma TRAIL levels predict short-term adverse events in normotensive patients with acute PE. The combination of TRAIL and hs-cTnI as a biomarker-based risk stratification strategy has a similar risk classification effect in normotensive patients with acute PE.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Shihai Liu, Jing Qiu, Guifang He, Weitai He, Changchang Liu, Duo Cai, Huazheng Pan
Summary: The interaction between TRAIL and IER3 can induce apoptotic death of HCC cells and inhibit their proliferation and migration by inhibiting Wnt/beta-catenin signaling. This TRAIL/IER3/beta-catenin axis may serve as a viable therapeutic target for HCC patients.
CANCER CELL INTERNATIONAL
(2021)
Article
Pharmacology & Pharmacy
Yu Ren, Xue Wang, Shuaishuai Huang, Yangkai Xu, Guobin Weng, Rui Yu
Summary: In this study, we found that alternol sensitized renal carcinoma cells to TRAIL-induced apoptosis by inhibiting antiapoptotic proteins, upregulating DR5 levels, ROS generation, and the CHOP pathway, thus enhancing TRAIL-mediated apoptosis.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Immunology
Ehsan Razeghian, Wanich Suksatan, Heshu Sulaiman Rahman, Dmitry O. Bokov, Walid Kamal Abdelbasset, Ali Hassanzadeh, Faroogh Marofi, Mahboubeh Yazdanifar, Mostafa Jarahian
Summary: TRAIL, as an immune cytokine, has the ability to selectively eliminate tumor cells but faces resistance issues. Studies have shown that overcoming TRAIL resistance can be achieved through combined treatment with other antitumor agents, the utilization of human MSCs and NPs for TRAIL delivery. These approaches show promise in enhancing the therapeutic efficacy and survival rate in cancer treatment.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Hojjat Alizadeh Zeinabad, Eva Szegezdi
Summary: TRAIL, as a promising anticancer drug with low toxicity, has not been successfully translated into a therapeutic molecule due to its short in vivo half-life and tumor cells' resistance. Nanotechnology shows potential to overcome these limitations and offers better solutions.
Article
Oncology
K. M. A. Zinnah, Sang-Youel Park
Summary: The study demonstrated the mechanism behind the synergistic anticancer effect of amitriptyline and TRAIL, showing that amitriptyline increases TRAIL-induced apoptosis by upregulating death receptors DR4 and DR5. Inhibition of autophagy by amitriptyline was also shown to enhance DR4 and DR5 expression.
Article
Medicine, Research & Experimental
Tianshan She, Qiuxiao Shi, Zhao Li, Yanru Feng, Hao Yang, Ze Tao, Heng Li, Jie Chen, Shisheng Wang, Yan Liang, Jingqiu Cheng, Xiaofeng Lu
Summary: Chemotherapeutic multidrug resistance (MDR) and TRAIL resistance are common in colorectal cancer (CRC) cells. Combination therapy of long-acting TRAIL and tumor-cell targeted photodynamic therapy (PDT) shows promising results in combating CRC with both types of resistance.
Article
Chemistry, Multidisciplinary
Tianshan She, Fen Yang, Shiyuan Chen, Hao Yang, Ze Tao, Huimin Xing, Jie Chen, Huansheng Chang, Hongyu Lu, Tao Su, Youmei Jin, Yi Zhong, Jingqiu Cheng, Hong Zhu, Xiaofeng Lu
Summary: The clinical application of TRAIL is limited by its inefficient induction of apoptosis in tumor cells. Superglue-mediated hyperoligomerization of TRAIL can increase its valency and improve its efficacy. In this study, minimal superglue peptide pairs were fused to the TRAIL promoter to create superglue-fusion TRAIL variants. These variants showed high expression and trimerization similar to native TRAIL. With the help of Snoopligase or SpyStapler, these variants could be crosslinked into hexavalent TRAIL variants. The hexavalent SnHexaTR variant produced by Snoopligase showed the highest yield and exhibited 10-40 times greater cytotoxicity than native TRAIL in tumor cells. It also had a longer half-life and greater tumor uptake, leading to the eradication of tumor xenografts. Hexavalent SnHexaTR, as a novel anticancer agent candidate, has great potential for clinical application in cancer therapy.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Cardiac & Cardiovascular Systems
Suneela Zaigham, Magnus Dencker, Magnus K. Karlsson, Ola Thorsson, Per Wollmer
Summary: This study found that elevated TRAIL levels are associated with impaired lung function in school-aged children, especially with significant associations with markers of pulmonary airflow obstruction.
RESPIRATORY MEDICINE
(2021)
Article
Oncology
Nagamani Vunnam, Malaney C. Young, Elly E. Liao, Chih Hung Lo, Evan Huber, MaryJane Been, David D. Thomas, Jonathan N. Sachs
Summary: Although nimesulide has been taken off the market due to hepatotoxicity, it is still used as a valuable research tool for developing new anticancer drugs. Several studies have been conducted to modify its structure and develop more potent anticancer agents. Understanding the mechanism of action for nimesulide is crucial in realizing its potential.
CANCER BIOLOGY & THERAPY
(2023)